Scarica l'app Stockscreener
7.20
2.44%
-0.18
Pre-mercato:
7.20
Precedente Chiudi:
$7.38
Aprire:
$7.32
Volume 24 ore:
47,710
Relative Volume:
0.43
Capitalizzazione di mercato:
$46.46M
Reddito:
$5.75M
Utile/perdita netta:
$-38.96M
Rapporto P/E:
-0.5774
EPS:
-12.47
Flusso di cassa netto:
$-32.63M
1 W Prestazione:
-3.36%
1M Prestazione:
+23.08%
6M Prestazione:
-33.82%
1 anno Prestazione:
+23.08%
Intervallo 1D:
$7.13
$7.6886
Intervallo di 1 settimana:
$7.00
$7.95
Portata 52W:
$2.92
$11.20
Kala Bio Inc Stock (KALA) Company Profile
Nome
Kala Bio Inc
Settore
Industria
Telefono
781-996-5252
Indirizzo
1167 MASSACHUSETTS AVENUE, ARLINGTON, MA
Confronta KALA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KALA
Kala Bio Inc
|
7.20 | 47.62M | 5.75M | -38.96M | -32.63M | -12.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
374.46 | 93.98B | 11.42B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
435.00 | 57.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.94 | 59.67B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
638.90 | 40.50B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
289.75 | 34.26B | 3.81B | -644.79M | -669.77M | -6.24 |
Kala Bio Inc Stock (KALA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-11 | Iniziato | Ladenburg Thalmann | Buy |
| 2022-03-30 | Downgrade | JP Morgan | Neutral → Underweight |
| 2021-08-06 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-09-14 | Downgrade | Jefferies | Buy → Hold |
| 2020-07-23 | Iniziato | Northland Capital | Outperform |
| 2020-06-01 | Ripresa | Oppenheimer | Outperform |
| 2020-05-27 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-09 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-12-17 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-03-14 | Iniziato | Jefferies | Buy |
Mostra tutto
Kala Bio Inc Borsa (KALA) Ultime notizie
Technical analysis overview for KALA BIO Inc. stockPrice Movement and Market Sentiment Analysis - Newser
What makes KALA BIO Inc. stock price move sharplyFree Risk Managed Intraday Trade Alerts - Newser
Using portfolio simulators with KALA BIO Inc. includedBreakout Screener With Alert Based Timing - Newser
Can volume confirm reversal in KALA BIO Inc.Free AI Screening for Swing Trade Picks - Newser
Is KALA BIO Inc. a Top Dividend Stock to Watch in 2025Profitable Trading Blueprint with Entry Zones - Newser
Trend analysis for KALA BIO Inc. this weekWeekly Trend Watch with Market Signals - Newser
How KALA BIO Inc. stock performs during market volatilityAccurate Forecast System with AI Support - Newser
Why KALA BIO Inc. stock attracts strong analyst attentionFree Beginner Friendly Stock Selection Guide - Newser
What drives KALA BIO Inc.’s stock priceStocks with 300% Upside - sisaissue.com
KALA BIO Inc. stock trend forecastEntry Opportunity Screener with Confirmation - Newser
Comparing KALA BIO Inc. in custom built stock radarsWatchlist Generator With Real-Time Entry - Newser
KALA BIO: Q2 Earnings Snapshot - Greenwich Time
KALA BIO (NASDAQ:KALA) Stock Rating Lowered by Wall Street Zen - Defense World
Can KALA BIO Inc. recover in the next quarterFree Community Entry Consensus Trade Ideas - Newser
Momentum divergence signals in KALA BIO Inc. chartShort-Term Profit Alert With Entry Forecast - Newser
Kala Bio (KALA) Q2 Loss Widens 15% - AOL.com
KALA BIO Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Biotech's Long Game: Assessing KALA BIO's Q2 Loss in the Context of Strategic Innovation - AInvest
Kala Bio (KALA) Q2 Loss Widens 15% - The Motley Fool
KALA BIO, Inc. Completes Patient Enrollment in Phase 2b CHASE Trial for KPI-012 in Persistent Corneal Epithelial Defect, Reports Financial Results and Upcoming Milestones - Quiver Quantitative
KALA BIO, Inc. SEC 10-Q Report - TradingView
KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference | KALA Stock News - GuruFocus
KALA BIO, Inc. to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference on August 13, 2025 - Quiver Quantitative
KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference - GlobeNewswire
KALA BIO Showcases Breakthrough Eye Disease Treatments at Major Ophthalmology Conference - Stock Titan
What candlestick patterns are forming on KALA BIO Inc.Machine Learning Stock Price Forecast Tool - Newser
KALA BIO Inc. Company’s Quarterly Earnings Growth: What the Numbers SayDownside Risk Evaluation and Stock Analysis - Newser
What is the dividend policy of KALA BIO Inc. stockUnlock market-leading stock analysis - Jammu Links News
Should I hold or sell KALA BIO Inc. stock in 2025Capitalize on strategic market trends - Jammu Links News
How volatile is KALA BIO Inc. stock compared to the marketRapid growth opportunities - Jammu Links News
Is KALA BIO Inc. stock overvalued or undervaluedAchieve consistent double-digit growth rates - Jammu Links News
What institutional investors are buying KALA BIO Inc. stockCapitalize on proven investment strategies - Jammu Links News
How does KALA BIO Inc. compare to its industry peersOutstanding capital returns - Jammu Links News
Is KALA BIO Inc. a growth stock or a value stockAchieve exceptional returns with expert guidance - Jammu Links News
What is the risk reward ratio of investing in KALA BIO Inc. stockGet professional guidance for market timing - Jammu Links News
Is it the right time to buy KALA BIO Inc. stockFree Stock Market Trend Analysis - Jammu Links News
Why is KALA BIO Inc. stock attracting strong analyst attentionInvest confidently with daily market forecasts - Jammu Links News
Is KALA BIO Inc. a good long term investmentFree Stock Market Trend Analysis - Jammu Links News
Kala Bio Inc Azioni (KALA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.02%
3.70%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):